Inclusion Criteria:  Age 18 years or older Histologically or cytologically confirmed pancreatic adenocarcinoma. Must have locally advanced, recurrent, or metastatic disease ineligible for curative intent treatment(s) and eligible for first line systemic treatment. Must have radiologic imaging with a computed tomography (CT) scan or magnetic resonance imaging (MRI) within 22 days of study entry Must have at least one measurable lesion according to RECIST 1.1 Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 Adequate gastrointestinal (GI), bone marrow, liver and kidney function Life expectancy minimum of > 12 weeks Adequate recovery from surgery to Grade 1 or baseline with at least 28 days from time of major surgery  Exclusion Criteria:  Received last dose of chemotherapy (neoadjuvant or adjuvant), surgery, or radiation treatment with curative intent within 6 months prior to study entry Islet-cell neoplasms Prior malignancy within the past 3 years except adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast Symptomatic uncontrolled central nervous system (CNS) metastasis or brain metastases unless adequately treated and controlled Evidence of clinically significant third spacing (e.g. pleural effusion, ascites, anasarca, etc.) within 28 days prior to study entry Serious active infection requiring IV antibiotics and/or hospitalization at study entry Active human immune deficiency (HIV) syndrome, hepatitis B, hepatitis C, or other active viral illness